News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ipsen (IPN.PA) Announces A Step Forward In The Resupply Of Increlex® (Mecasermin [rDNA Origin] Injection) In The U.S.



5/13/2014 8:27:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that a supply of Increlex® (mecasermin [rDNA origin] injection) will be available in the U.S. starting June 2, 2014. In collaboration with the U.S. Food and Drug Administration (FDA), Ipsen is releasing one batch of Increlex’s active ingredient. Ipsen anticipates that additional lots will be released in the coming months, as the company continues to work closely with the FDA to make additional Increlex lots available as soon as possible.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Ipsen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES